Compare Globus Medical Inc. Class A Common Stock (GMED) vs D Wave Quantum Inc (QBTS) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

QBTS (D-Wave Quantum Inc.) trades at $13.38, down 2.62% on the day, reflecting a bearish technical trend amid negative earnings and high valuation metrics. The company reported a net loss of $355.06M on $24.59M revenue for 2025, with a net income margin of -2,001.59%. Recent news highlights ongoing fraud investigations by multiple law firms, though the company continues to advance its quantum computing technology, such as the launch of a gate-model simulator beta program.

The stock presents a high-risk, speculative opportunity with a unanimous analyst buy rating and a consensus price target of $34.38, implying significant upside. However, substantial financial losses, negative cash flow from operations, and legal uncertainties pose severe risks. Investors should weigh the long-term potential of quantum computing against immediate financial instability and litigation overhangs.